Boston ScientificNYSE: BSX

Research shows that the stroke risk reduction device works as well as oral anticoagulants for patients with atrial fibrillation after a cardiac ablation. On November 16, 2024, Boston Scientific Corporation announced encouraging three-year results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.

Boston Scientific Corporation (NYSE:BSX) will be participating in the UBS Global Healthcare Conference on November 12, 2024, at 10:15 AM ET. The company representatives include Jonathan Monson, Senior Vice President of Investor Relations, and Nick Spadea-Anello, Vice President and General Manager of Interventional Cardiology. Danielle Antalffy from UBS will also be part of the conference call, welcoming everyone in the morning.

Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has included the "Kidney Stone Management Market Report and Forecast 2024-2032" in its collection. In 2023, the global kidney stone management market was valued at USD 1.80 billion. It is projected to grow at a rate of 5.20% annually from 2024 to 2032, reaching an estimated USD 2.84 billion by 2032.

Boston Scientific Corporation (NYSE: BSX) has announced that it will acquire Cortex, Inc., a company under Ajax Health, to enhance its electrophysiology offerings. This acquisition aims to improve the treatment options for complex atrial fibrillation. The agreement was made public on November 4, 2024, in Marlborough, Massachusetts.

Boston Scientific Corporation (NYSE:BSX) will hold a Business Update Earnings Conference Call on October 30, 2024, at 4:00 PM ET. The call will feature company representatives, including Jonathan Monson, Joseph Fitzgerald, Lance Bates, Janar Sathananthan, and Kenneth Stein. Please be aware that this event is being recorded.

No matter if you focus on value, growth, or momentum investing, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key benefits of the Zacks Premium research service.

BSX's Endoscopy division in MedSurg is benefiting from high global demand for its wide variety of gastrointestinal and pulmonary treatment solutions.

Boston Scientific, a company that makes medical devices, is expected to keep growing its profits over the next few years. This positive outlook is supported by its strong history, good profit margins, product pipeline, and smart use of capital. Although other analysts on Seeking Alpha have given it a Hold rating this year, I believe it deserves a Buy rating and anticipate a nearly 15% increase in its price over the next year.

Boston Scientific (BSX) has strong growth characteristics that may enable it to significantly exceed market performance.